Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Sarcoma 1Lymphoid 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 1Lymphoma 1Intermittent Fasting 1Fasting 1

Interventions

Cyclophosphamide 342Rituximab 304Vincristine 157Doxorubicin 154venetoclax 153fludarabine 153Specimen Handling 152Prednisone 150Biopsy 122Magnetic Resonance Spectroscopy 117obinutuzumab 116Lenalidomide 109Dexamethasone 104Cytarabine 97ibrutinib 95Etoposide 92fludarabine phosphate 87Methotrexate 84acalabrutinib 78Bendamustine Hydrochloride 72zanubrutinib 71blinatumomab 63pembrolizumab 62CT-P10 60Gemcitabine 51Nivolumab 45glofitamab 44Calcium Dobesilate 44Mercaptopurine 43prednylidene 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Angptl4 protein, mouse × Lymphoid × 1 year × Clear all
NCT06645093 2026-03-10

FasteStudien

University of Oslo

Phase NA Enrolling by invitation
40 enrolled
Lymphoid

Intermittent Fasting, Fasting, Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡